WorldHeart HeartSaver R&D Consolidation: 25% Personnel Cut Planned
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart's plan to merge the HeartSaverVAD and HeartSaverVADII development programs will save $10 mil. per year and help the firm reach profitability by 2004, the left-ventricular assist device maker predicts
You may also be interested in...
Medicare Coverage Might Make LVADs Attractive Acquisition Targets
Large cardiovascular device firms may seek to acquire or enter distribution agreements with LVAD developers, following MCAC's positive review of left-ventricular assist devices as a destination therapy
Medicare Coverage Might Make LVADs Attractive Acquisition Targets
Large cardiovascular device firms may seek to acquire or enter distribution agreements with LVAD developers, following MCAC's positive review of left-ventricular assist devices as a destination therapy
WorldHeart
PMA supplement covering Novacor left ventricular assist system as an alternative to transplant for end-stage heart failure patients is submitted to FDA, firm reports Aug. 15. WorldHeart has requested that the agency grant it expedited review. A total of 270 patients have received the Novacor in North American clinical trials, in addition to 1,349 implants under the existing "bridge-to-transplant" indication (11"The Gray Sheet" June 17, 2002, p. 36)...